TEVA-ELETRIPTAN 40 MG — DIN 02382105
ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) : 40 MG · TEVA CANADA LIMITED · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is TEVA-ELETRIPTAN?
TEVA-ELETRIPTAN 40 MG contains ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) : 40 MG. It is listed in the Health Canada Drug Product Database under DIN 02382105, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 20-Dec-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-ELETRIPTAN used for?
Acute treatment of migraine with or without aura in adults. Not for prophylactic therapy or hemiplegic, ophthalmoplegic, or basilar migraine.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Eletriptan cost around the world?
Eletriptan is listed on 12 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Italy | prezzo al pubblico (classe A) | 6 | 16 | EUR███.██ |
| Saudi Arabia | public | 5 | 9 | SAR███.██ |
| Sweden | AIP (pharmacy purchase price) | 3 | 5 | SEK███.██ |
| Austria | KVP (Kassenverkaufspreis) | 2 | 4 | EUR███.██ |
| Czechia | max producer price (ex-factory) | 1 | 4 | CZK███.██ |
| Morocco | PPV (public price) | 1 | 4 | MAD███.██ |
| Greece | producer price (ex-factory) | 3 | 3 | EUR███.██ |
| Hungary | producer price (ex-factory) | 2 | 3 | HUF███.██ |
| South Africa | single exit price | 2 | 3 | ZAR███.██ |
| Australia | ex-manufacturer | 1 | 2 | AUD███.██ |
| Iceland | max wholesale | 1 | 2 | ISK███.██ |
| Luxembourg | reimbursement | 1 | 1 | EUR███.██ |
56 pack listings across 28 brand entries and 11 price bases, refreshed 08 Sep 2026. Ranges span every Eletriptan pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Eletriptan in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
9 holders have a Canadian DIN containing Eletriptan, across 20 DINs, of which 16 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| APOTEX INC | 4 | 2 | APO-ELETRIPTAN, APO-ELETRIPTAN TABLETS | Sourceable in Canada |
| AURO PHARMA INC | 2 | 2 | AURO-ELETRIPTAN | Sourceable in Canada |
| BGP PHARMA ULC | 2 | 2 | RELPAX | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 2 | 2 | JAMP ELETRIPTAN | Sourceable in Canada |
| MYLAN PHARMACEUTICALS ULC | 2 | 2 | MYLAN-ELETRIPTAN | Sourceable in Canada |
| PRO DOC LIMITEE | 2 | 2 | PRO-ELETRIPTAN | Sourceable in Canada |
| SANIS HEALTH INC | 2 | 2 | ELETRIPTAN | Sourceable in Canada |
| TEVA CANADA LIMITED | 2 | 2 | TEVA-ELETRIPTAN | Sourceable in Canada |
| PHARMASCIENCE INC | 2 | 0 | PMS-ELETRIPTAN | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 40 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Not explicitly detailed in the provided text (mentions 20 mg and 40 mg strengths). |
| Storage | Not explicitly detailed in the provided text (Table of Contents points to page 20, but text ends earlier). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Eletriptan |
|---|---|
| ATC code | N02CC06 |
| AHFS class | 28:32.28 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02382105 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2382105 |
| Brand name | TEVA-ELETRIPTAN |
| Generic / active ingredient | ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) : 40 MG |
| Market authorization holder | TEVA CANADA LIMITED |
| Health Canada schedule | Prescription |
| ATC code | N02CC06 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N02CC |
| Current status | MARKETED |
| Status date | 20-Dec-2013 |
| Original market date | 2013-12-20 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Acute treatment of migraine. Available in 20 mg and 40 mg. Contraindicated within 72 hours of potent CYP3A4 inhibitors. Max daily dose not specified in snippet but caution with renal impairment.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Ischemic cardiac, cerebrovascular, or peripheral vascular syndromes; valvular heart disease; arrhythmias; uncontrolled hypertension; severe hepatic impairment; use within 72h of potent CYP3A4 inhibitors.
Warnings and precautions
Risk of myocardial ischemia/infarction; cerebrovascular events; serotonin syndrome with SSRIs/SNRIs; transient blood pressure increases; corneal opacities observed in animal studies.
Is Eletriptan in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by SANIS HEALTH INC, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
16 of 20 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-ELETRIPTAN TABLETS | 20 MG | TABLET | APOTEX INC | MARKETED | 02518015 |
| APO-ELETRIPTAN TABLETS | 40 MG | TABLET | APOTEX INC | MARKETED | 02518023 |
| AURO-ELETRIPTAN | 20 MG | TABLET | AURO PHARMA INC | MARKETED | 02479451 |
| AURO-ELETRIPTAN | 40 MG | TABLET | AURO PHARMA INC | MARKETED | 02479478 |
| ELETRIPTAN | 40 MG | TABLET | SANIS HEALTH INC | MARKETED | 02511274 |
| ELETRIPTAN | 20 MG | TABLET | SANIS HEALTH INC | MARKETED | 02511266 |
| JAMP ELETRIPTAN | 20 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02493683 |
| JAMP ELETRIPTAN | 40 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02493691 |
| MYLAN-ELETRIPTAN | 40 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | 02342243 |
| MYLAN-ELETRIPTAN | 20 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | 02342235 |
2 · Same class — other molecules in ATC N02CC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Rizatriptan | ACCEL-RIZATRIPTAN ODT · ACT RIZATRIPTAN · ACT RIZATRIPTAN ODT · AG-RIZATRIPTAN ODT · +36 more | 85 | 34 | Yes |
| Sumatriptan | ACT SUMATRIPTAN · AG-SUMATRIPTAN · APO-SUMATRIPTAN · AVA-SUMATRIPTAN · +27 more | 80 | 32 | Yes |
| Eletriptan | APO-ELETRIPTAN · APO-ELETRIPTAN TABLETS · AURO-ELETRIPTAN · ELETRIPTAN · +6 more | 20 | 16 | Yes |
| Zolmitriptan | AG-ZOLMITRIPTAN ODT · APO-ZOLMITRIPTAN · APO-ZOLMITRIPTAN RAPID · AURO-ZOLMITRIPTAN · +33 more | 45 | 15 | Yes |
| Almotriptan | ALMOTRIPTAN · APO-ALMOTRIPTAN · AXERT 12.5MG · AXERT 6.25MG · +5 more | 13 | 6 | Yes |
| Frovatriptan | APO-FROVATRIPTAN · FROVA · FROVATRIPTAN · JAMP FROVATRIPTAN · +2 more | 6 | 5 | Yes |
| Naratriptan | AMERGE · APO-NARATRIPTAN · SANDOZ NARATRIPTAN · TEVA-NARATRIPTAN | 7 | 3 | Yes |
| Sumatriptan And Naproxen | SUVEXX | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N02C
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N02CD | Atogepant · Eptinezumab · Erenumab · Fremanezumab · Galcanezumab · +2 more | 17 | 15 |
| N02CA | Dihydroergotamine · Ergotamine · Ergotamine, Combinations Excl. Psycholeptics · Ergotamine, Combinations With Psycholeptics · Methysergide | 15 | 2 |
| N02CX | Clonidine · Pizotifen | 3 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is TEVA-ELETRIPTAN called?
The same molecule, Eletriptan, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Relpax | Latin | Australia, Czechia, Iceland, Morocco |
| Eleptan | Latin | Saudi Arabia |
| Eletriptan Orion | Latin | Sweden |
| Migrotan | Latin | Saudi Arabia |
| Relpax® | Latin | Sweden |
| Eletriptan Pensa | Latin | Sweden |
| Eletrivaz | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.